Sodium pentosan polysulfate efficacy as thromboprophylaxis agent in high‐risk women following gynecological surgery

摘要

Abstract Aim Sodium pentosan polysulfate (Na‐PPS) is a plant‐based agent that has similar action with low‐molecular‐weight heparin. It inhibits factor Xa, preventing blood clot formation. To date, its use in clinical practice as thromboprophylaxis agent is still limited. In addition, the efficacy and safety profile of this agent was not robustly reported globally, especially for countries with major Muslim population. We hypothesized that Na‐PPS was equally effective as the standard thromboprophylaxis. We aim to compare the efficacy and safety of Na‐PPS against standard agent (fondaparinux or enoxaparin). Methods This was a randomized control, open‐label trial. Women underwent major gynecological surgery were randomized to receive either subcutaneous 50?mg of Na‐PPS twice daily or subcutaneous enoxaparin 40?mg once daily. Fondaparinux 2.5?mg once daily was given to Muslim women as an alternative to enoxaparin. The treatment was started 6?h postoperatively, for at least 3?days. All the patients received thromboembolic deterrent stockings. The primary efficacy outcome was venous thromboembolism up to 3?days postsurgery. The main safety outcomes were minor and major bleeding. Results Among 109 participants, there was no incidence of venous thromboembolism. None of the women developed major bleeding. Minor bleeding was observed in 28.3% (15/53) and 5.4% (3/56) of Na‐PPS and standard thromboprophylaxis group, respectively ( P =?0.001). Conclusion Na‐PPS was associated with increased risk of minor bleeding. There was insufficient data to conclude its efficacy as thromboprophylaxis. Further research is needed to evaluate Na‐PPS safety as a standard thromboprophylactic agent.